Loading...
•
Sep 30
Paysign Q3 2025 Earnings Report
Paysign posted record Q3 revenue and net income growth driven by strong performance in patient affordability and plasma programs.
Key Takeaways
Paysign delivered strong Q3 2025 results with record revenue of $21.6M, driven by 141.9% growth in its pharma patient affordability business and 12.4% growth in plasma. Net income rose 54.2% to $2.2M, reflecting operational efficiencies and growing program count.
Revenue grew 41.6% YoY to $21.6M, driven by pharma and plasma segments.
Net income rose 54.2% YoY to $2.22M with EPS of $0.04.
Pharma patient affordability revenue increased 141.9% to $7.92M with 105 active programs.
Exited Q3 with 595 plasma centers and $7.53M in unrestricted cash.
Paysign
Paysign
Paysign Revenue by Segment
Revenue by Segment
Plasma Revenue
CapyFin.comPatient Affordability Revenue
CapyFin.comOther Revenue
CapyFin.com Forward Guidance
Paysign expects Q4 2025 to mirror Q3 with flat plasma revenue, growth in affordability programs, and seasonally lower claim activity. FY25 revenue is projected between $80.5M and $81.5M, led by patient affordability.
Positive Outlook
- Full-year revenue guidance increased to $80.5M–$81.5M.
- Patient affordability revenue expected to grow over 155% YoY.
- Full-year adjusted EBITDA expected between $19M and $20M.
- Gross margins projected to improve to ~60%.
- Net margin expected to reach ~9.3%, up 280bps YoY.
Challenges Ahead
- Plasma inventory oversupply remains a headwind until 1H 2026.
- Flat plasma revenue expected in Q4.
- Seasonally lower claim activity forecasted in Q4.
- Interest income expected to decline due to lower rates.
- Increased expenses due to platform and service center investments.
Revenue & Expenses
Visualization of income flow from segment revenue to net income